YMAB241220P30000
- 0.00
- 0.000.00%
Y-mAbs Therapeutics Newsroom
JonesTrading Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $23
Y-mAbs Therapeutics Analyst Ratings
H.C. Wainwright Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $22
Promising Preclinical Data on CD38-SADA Justifies Buy Rating for Y-Mabs Therapeutics
CCORF Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $26
Brookline Capital Initiates Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $17
Y-mAbs Therapeutics Initiated With a Buy at Brookline on Danyelza Potential
Brookline Capital Initiates Coverage On Y-mAbs Therapeutics With Buy Rating, Announces Price Target of $17
Oppenheimer Initiates Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $23
Oppenheimer Initiates Coverage On Y-mAbs Therapeutics With Outperform Rating, Announces Price Target of $23
Y-mAbs Therapeutics Analyst Ratings
H.C. Wainwright Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $22
JonesTrading Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $23
Morgan Stanley Maintains Y-mAbs Therapeutics(YMAB.US) With Sell Rating, Maintains Target Price $11
Truist Financial Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $21
Truist Financial Remains a Buy on Y-Mabs Therapeutics (YMAB)
Y-Mabs Therapeutics: Promising Pipeline Developments and Strong Revenue Projections Justify Buy Rating
Morgan Stanley Maintains Y-mAbs Therapeutics(YMAB.US) With Sell Rating, Maintains Target Price $11
Truist Financial Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating
JonesTrading Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $23